Does Imunon disclose any related-party relationships for new interim CFO Josh Blacher?

Imunon reports that the selection of Josh Blacher was not made pursuant to any arrangement with another person, that he has no family relationships with directors or executive officers, and that he has no material interests in transactions requiring disclosure under Item 404(a) of Regulation S-K.

Imunon (NASDAQ: IMNN) appoints Josh Blacher as interim CFO

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Imunon, Inc. announced that interim Chief Financial Officer Jeffrey Church plans to retire from his role effective July 1, 2026. To support continuity, he will remain with the company as a consultant under an amended agreement with a $10,000 monthly retainer, cancellable on two business days’ notice.

Effective the same date, Imunon appointed Josh Blacher as its new interim Chief Financial Officer through a master services agreement with Danforth Health, Inc. Imunon will pay Danforth $475 per hour for his CFO services. The filing notes Mr. Church’s departure is due to retirement and not related to any disagreement with management, and confirms that Mr. Blacher has no disclosed related-party relationships or conflicts.

8-K Event Classification

2 items: 5.02, 9.01

2 items

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Retirement effective date: July 1, 2026 Consulting retainer: $10,000 per month CFO services rate: $475 per hour +3 more

6 metrics

Retirement effective date July 1, 2026 Jeffrey Church retires as interim Chief Financial Officer

Consulting retainer $10,000 per month Monthly retainer for Jeffrey Church under amended consulting agreement

CFO services rate $475 per hour Hourly rate Imunon pays Danforth for Josh Blacher’s CFO services

Agreement date June 24, 2026 Date of master services agreement between Imunon and Danforth

Interim CFO start date January 2026 Start of Jeffrey Church’s service as interim Chief Financial Officer

Age of new interim CFO 54 years Age of interim Chief Financial Officer Josh Blacher

Key Terms

interim Chief Financial Officer, master services agreement, Regulation S-K, principal financial officer, +1 more

5 terms

interim Chief Financial Officer financial

"Retirement of interim Chief Financial Officer On June 29, 2026, Jeffrey Church informed Imunon, Inc."

An interim chief financial officer is a temporary leader responsible for managing a company's financial activities, such as budgeting, financial planning, and reporting, during a transitional period. Think of it as filling in for a key manager until a permanent replacement is found. For investors, this role is important because it ensures financial stability and clear guidance during times of change or uncertainty.

master services agreement financial

"to serve as the Company’s new interim Chief Financial Officer under a master services agreement (the “Agreement”), dated June 24, 2026"

A master services agreement is a standing contract that sets the main terms, responsibilities, pricing framework and processes for future work between two parties, allowing individual projects or orders to be added later without renegotiating core terms. For investors, it signals predictability and reduced legal friction around revenue streams and costs—like a subscription plan for services that makes future income and obligations easier to forecast and value.

Regulation S-K regulatory

"no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"

A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.

principal financial officer financial

"Mr. Blacher will serve as the Company’s principal financial officer and principal accounting officer."

The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.

consulting role financial

"he will continue in a consulting role with the Company."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

Available on EDGAR 06/30/2026 - 04:32 PM Accepted by SEC EDGAR 06/30/2026 - 04:30 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 29, 2026

Imunon, Inc.

(Exact name of registrant as specified in its Charter)

Delaware

001-15911

52-1256615

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

997 Lenox Drive, Suite 100, Lawrenceville, NJ		08648-2311
(Address of principal executive offices)		(Zip Code)

(609) 896-9100

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act

Title of each class		Trading symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		IMNN		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Retirement of interim Chief Financial Officer

On June 29, 2026, Jeffrey Church informed Imunon, Inc. (the “Company”) of his intent to retire from the position of interim Chief Financial Officer (a position he has held since January of 2026), effective July 1, 2026 (the “Retirement Date”). To help ensure a smooth transition of his responsibilities to his successor, Mr. Church and the Company agreed that he will continue in a consulting role with the Company. The Company and Mr. Church amended the Consulting Agreement, effective July 1, 2026, pursuant to which, the Company agreed to pay Mr. Church a monthly retainer of $10,000 (that may be terminated upon 2 business days’ notice). Mr. Church’s departure is due to retirement and is without any disagreements with management.

Appointment of New Chief Financial Officer

As a result of Mr. Church’s retirement, effective July 1, 2026, the Company appointed Josh Blacher to serve as the Company’s new interim Chief Financial Officer under a master services agreement (the “Agreement”), dated June 24, 2026, between the Company and Danforth Health, Inc., a financial advisory services firm (“Danforth”). Mr. Blacher will serve as the Company’s principal financial officer and principal accounting officer.

Mr. Blacher, age 54, currently serves as an employee of Danforth since September 2022, where he has worked as a chief financial officer in a consulting capacity for a number of life sciences companies as well as Managing Partner of Columbus Circle Capital LLC since August 2019. In his capacity as a consultant of Danforth, he has served as Chief Financial Officer of BullFrog AI Holdings, Inc. (Nasdaq: BFRG) since December 2024, among others. During his tenure at Columbus Circle Capital, Mr. Blacher has served as chief financial officer at several public and private companies. Prior to his tenure at Columbus Circle Capital, Mr. Blacher served as Chief Business Officer at Inmed Pharmaceuticals (Nasdaq: INM) from April 2018 to August 2019, as Chief Financial Officer of Therapix Biosciences (Nasdaq: TRPX) from April 2017 to April 2018, and as Chief Financial Officer at Galmed Pharmaceuticals (Nasdaq: GLMD) from October 2014 to March 2017. Earlier in his career, Mr. Blacher served in senior capacities at Teva Pharmaceuticals, Deutsche Asset Management and Morgan Stanley. Mr. Blacher holds a Bachelor of Arts in Economics from Yeshiva University and a Master of Business Administration in Finance from Columbia Business School.

Under the Agreement, the Company will pay Danforth $475 per hour for Mr. Blacher’s service as the Company’s Chief Financial Officer. The foregoing description of the Agreement is not complete and is qualified in its entirety by reference to the Agreement, which is filed herewith as Exhibit 10.1 and incorporated by reference herein.

The selection of Mr. Blacher to serve as principal financial officer and principal accounting officer was not pursuant to any arrangement or understanding between him and any other person. Mr. Blacher has no family relationship with any director or executive officer of the Company, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K of the Securities Exchange Act of 1934, as amended.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description

10.1		Master Services Agreement, dated June 24, 2026, by and between Imunon, Inc. and Danforth Health, Inc.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	IMUNON INC.

Dated: June 30, 2026	By:	/s/ Susan Eylward
		Susan Eylward
		General Counsel and Corporate Secretary

Source: View Original Filing on SEC EDGAR

FAQ

What leadership change did Imunon (IMNN) disclose in this 8-K filing?

Imunon disclosed that interim Chief Financial Officer Jeffrey Church will retire from his interim CFO role effective July 1, 2026. He will transition to a consulting position, while a new interim CFO, Josh Blacher, is appointed through a master services agreement with Danforth Health, Inc.

When will Imunon’s interim CFO retirement and new appointment take effect?

Both changes take effect on July 1, 2026. On that date, Jeffrey Church’s service as interim Chief Financial Officer ends and he becomes a consultant, while Josh Blacher formally assumes responsibilities as interim Chief Financial Officer and principal financial and accounting officer.

How will Imunon (IMNN) compensate Jeffrey Church after his retirement as interim CFO?

After retiring as interim CFO, Jeffrey Church will continue as a consultant under an amended agreement. Imunon agreed to pay him a monthly retainer of $10,000, and either party may terminate this consulting arrangement on two business days’ notice, providing flexibility during the transition.

What are the key terms of Imunon’s agreement with Danforth for CFO services?

Under a master services agreement dated June 24, 2026, Imunon will pay Danforth Health, Inc. $475 per hour for the services of interim Chief Financial Officer Josh Blacher. Danforth, not Imunon directly, employs Mr. Blacher, who will act as principal financial and accounting officer.

Does Imunon report any disagreements linked to the interim CFO’s retirement?

The company states that Jeffrey Church’s departure from the interim Chief Financial Officer role is due to retirement and is without any disagreements with management. This clarification suggests the leadership transition is for personal and organizational reasons rather than dispute-driven causes.

Filing Exhibits & Attachments

18 documents

Agreements & Contracts

EX-10.1 EX-10.1 10.8 KB